The latest therapeutic options for lymphoma are mainly based on new drug therapies, mainly new targeted drugs Bruton’s tyrosine kinase (BTK) inhibitors and chimeric antigen receptor-T cell (CAR-T) therapy.
1. New targeted BTK inhibitors, such as ibrutinib and axatinib, have brought relatively good benefits to patients with relapsed or refractory disease, however, the prognosis for patients who have received ineffective treatment with BTK inhibitors or who have progressed after treatment is very poor.
2. Chimeric antigen receptor-T cell (CAR-T) therapy, which has become a hot spot of attention in the field of anti-tumor therapy.
CAR-T therapy is generally prepared by firstly obtaining patients’ T lymphocytes, then gene transduction, and then T cells are dose-expanded, washed and concentrated into cellular drugs, and finally infused back into patients to achieve the purpose of specifically killing tumor cells.
The above two treatment options are the latest treatment options for lymphoma, and it is recommended that patients choose a suitable treatment option for their own condition under the guidance of a professional doctor in order to obtain a better therapeutic effect. It is not recommended that patients buy the above drugs by themselves to avoid serious adverse consequences.